Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

Johnson & Johnson (J&J) significantly raised its full-year sales and adjusted EPS forecasts after reporting stronger-than-expected second-quarter results, driven by robust demand for its cancer drug Darzalex and strong performance in its medical device business. The company now projects full-year sales of $93.2 billion to $93.6 billion and adjusted EPS of $10.80 to $10.90, also benefiting from a reduction in anticipated tariff-related costs to $200 million. This positive update, which saw Q2 sales reach $23.74 billion and adjusted EPS hit $2.77 (both exceeding analyst estimates), led to a 1.1% rise in J&J's shares in premarket trading.

Analysis

Johnson & Johnson reported a strong second quarter, beating analyst estimates on both revenue and earnings, driven by robust performance in its medical device business and high demand for its cancer drug, Darzalex. The company posted Q2 adjusted EPS of $2.77 against expectations of $2.68, on sales of $23.74 billion versus a $22.84 billion consensus. Specifically, the medtech unit's sales grew 6.1% ex-currency to $8.54 billion, surpassing the $8.25 billion estimate, while Darzalex sales reached $3.54 billion, ahead of the expected $3.38 billion. This operational strength, combined with a significant reduction in anticipated full-year tariff-related costs from $400 million to $200 million, prompted the company to raise its full-year outlook. J&J now forecasts full-year sales between $93.2 billion and $93.6 billion, up from a prior range of $91 billion to $91.8 billion, and has raised its 2025 adjusted EPS forecast to between $10.80 and $10.90 from a previous $10.50 to $10.70. The positive results and upgraded guidance led to a 1.1% increase in the company's shares in premarket trading.

Key Decisions for Investors

• Investors should view the significant beat on Q2 revenue and EPS, driven by broad-based strength in both the medtech and pharmaceutical segments, as a strong bullish signal for the company's operational health.
• The upward revision to full-year sales guidance and the 2025 EPS forecast, which surpasses analyst consensus and is further supported by a $200 million reduction in anticipated tariff costs, suggests potential for continued earnings outperformance.
• Continued monitoring of sales momentum in the high-performing cancer drug Darzalex and the medtech division is critical, as these segments were the primary drivers of the quarterly beat and are key to achieving the new, higher financial targets.